Silverback Therapeutics (SBTX) Competitors

$8.56 +0.30 (+3.63%)

As of 05/1/2026

SBTX vs. AVTE, LWAC, ELYM, NLTX, and WHWK

Should you be buying Silverback Therapeutics stock or one of its competitors? The main competitors of Silverback Therapeutics include Aerovate Therapeutics (AVTE), LightWave Acquisition (LWAC), Eliem Therapeutics (ELYM), Neoleukin Therapeutics (NLTX), and Whitehawk Therapeutics (WHWK).

How does Silverback Therapeutics compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

: Silverback Therapeutics' return on equity of -29.62% beat Aerovate Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Aerovate Therapeutics N/A -90.19% -77.47%
Silverback Therapeutics N/A -29.62% -28.20%
: In the previous week, Aerovate Therapeutics had 1 more articles in the media than Silverback Therapeutics. MarketBeat recorded 1 mentions for Aerovate Therapeutics and 0 mentions for Silverback Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.75 beat Silverback Therapeutics' score of 0.00 indicating that Aerovate Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
Aerovate Therapeutics Positive
Silverback Therapeutics Neutral
: 74.9% of Silverback Therapeutics shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A
Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A
: Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Company	Overall Sentiment
Aerovate Therapeutics	Positive
Silverback Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

Summary

Aerovate Therapeutics and Silverback Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Silverback Therapeutics compare to LightWave Acquisition?

Silverback Therapeutics (NASDAQ:SBTX) and LightWave Acquisition (NASDAQ:LWAC) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

: LightWave Acquisition's return on equity of 0.00% beat Silverback Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Silverback Therapeutics N/A -29.62% -28.20%
LightWave Acquisition N/A N/A N/A
: In the previous week, Silverback Therapeutics' average media sentiment score of 0.00 equaled LightWave Acquisition'saverage media sentiment score.
Company Overall Sentiment
Silverback Therapeutics Neutral
LightWave Acquisition Neutral
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silverback Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
LightWave Acquisition
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: 74.9% of Silverback Therapeutics shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A
LightWave Acquisition N/A N/A N/A N/A N/A

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
LightWave Acquisition	N/A	N/A	N/A

Company	Overall Sentiment
Silverback Therapeutics	Neutral
LightWave Acquisition	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

LightWave Acquisition beats Silverback Therapeutics on 3 of the 5 factors compared between the two stocks.

How does Silverback Therapeutics compare to Eliem Therapeutics?

Silverback Therapeutics (NASDAQ:SBTX) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

: Silverback Therapeutics' return on equity of -29.62% beat Eliem Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Silverback Therapeutics N/A -29.62% -28.20%
Eliem Therapeutics N/A -47.03% -45.97%
: In the previous week, Eliem Therapeutics had 1 more articles in the media than Silverback Therapeutics. MarketBeat recorded 1 mentions for Eliem Therapeutics and 0 mentions for Silverback Therapeutics. Eliem Therapeutics' average media sentiment score of 0.67 beat Silverback Therapeutics' score of 0.00 indicating that Eliem Therapeutics is being referred to more favorably in the news media.
Company Overall Sentiment
Silverback Therapeutics Neutral
Eliem Therapeutics Positive
: 74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: Eliem Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A
Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A
: Silverback Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.39, indicating that its stock price is 139% less volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Eliem Therapeutics	N/A	-47.03%	-45.97%

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Eliem Therapeutics	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

Summary

Silverback Therapeutics beats Eliem Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Silverback Therapeutics compare to Neoleukin Therapeutics?

Silverback Therapeutics (NASDAQ:SBTX) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

: Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A
Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A
: 74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
: Silverback Therapeutics' return on equity of -29.62% beat Neoleukin Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Silverback Therapeutics N/A -29.62% -28.20%
Neoleukin Therapeutics N/A -37.22% -30.91%
: In the previous week, Neoleukin Therapeutics had 1 more articles in the media than Silverback Therapeutics. MarketBeat recorded 1 mentions for Neoleukin Therapeutics and 0 mentions for Silverback Therapeutics. Silverback Therapeutics' average media sentiment score of 0.00 equaled Neoleukin Therapeutics'average media sentiment score.
Company Overall Sentiment
Silverback Therapeutics Neutral
Neoleukin Therapeutics Neutral
: Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Neoleukin Therapeutics	Neutral

Summary

Silverback Therapeutics beats Neoleukin Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Silverback Therapeutics compare to Whitehawk Therapeutics?

Silverback Therapeutics (NASDAQ:SBTX) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

: Whitehawk Therapeutics has higher revenue and earnings than Silverback Therapeutics. Silverback Therapeutics is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A
Whitehawk Therapeutics $7.14M 29.15 -$20.60M $0.47 8.96
: 74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
: Silverback Therapeutics' return on equity of -29.62% beat Whitehawk Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Silverback Therapeutics N/A -29.62% -28.20%
Whitehawk Therapeutics N/A -62.88% -58.98%
: In the previous week, Whitehawk Therapeutics had 2 more articles in the media than Silverback Therapeutics. MarketBeat recorded 2 mentions for Whitehawk Therapeutics and 0 mentions for Silverback Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.16 beat Silverback Therapeutics' score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.
Company Overall Sentiment
Silverback Therapeutics Neutral
Whitehawk Therapeutics Positive
: Whitehawk Therapeutics has a consensus target price of $7.00, indicating a potential upside of 66.27%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Whitehawk Therapeutics is more favorable than Silverback Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silverback Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Whitehawk Therapeutics
1 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.50
: Silverback Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Whitehawk Therapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Whitehawk Therapeutics	$7.14M	29.15	-$20.60M	$0.47	8.96

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Whitehawk Therapeutics	N/A	-62.88%	-58.98%

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Whitehawk Therapeutics	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Whitehawk Therapeutics beats Silverback Therapeutics on 11 of the 14 factors compared between the two stocks.

Get Silverback Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SBTX vs. The Competition

Export

Metric	Silverback Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$308.66M	$886.55M	$6.25B	$11.77B
Dividend Yield	N/A	4.84%	2.74%	5.26%
P/E Ratio	-3.54	0.96	24.91	23.23
Price / Sales	N/A	120.65	504.56	75.49
Price / Cash	N/A	20.07	43.30	53.90
Price / Book	1.16	7.60	9.67	6.69
Net Income	-$89.48M	-$4.80M	$3.55B	$332.64M
7 Day Performance	7.67%	-0.05%	1.70%	2.01%
1 Month Performance	3.13%	5.50%	5.62%	9.19%
1 Year Performance	-40.80%	30.96%	34.42%	39.59%

Silverback Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SBTX Silverback Therapeutics	N/A	$8.56 +3.6%	N/A	N/A	$308.66M	N/A	N/A	83	High Trading Volume
AVTE Aerovate Therapeutics	N/A	$26.45 -1.5%	N/A	N/A	$766.65M	N/A	N/A	20	High Trading Volume
LWAC LightWave Acquisition	N/A	$10.18 flat	N/A	N/A	$306.21M	N/A	N/A	N/A
ELYM Eliem Therapeutics	N/A	$9.26 -2.5%	N/A	N/A	$275.50M	N/A	N/A	9	High Trading Volume
NLTX Neoleukin Therapeutics	N/A	$27.03 +0.3%	N/A	N/A	$254.03M	N/A	N/A	90	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SBTX) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silverback Therapeutics (SBTX) Competitors

SBTX vs. AVTE, LWAC, ELYM, NLTX, and WHWK

How does Silverback Therapeutics compare to Aerovate Therapeutics?

Summary

How does Silverback Therapeutics compare to LightWave Acquisition?

Summary

How does Silverback Therapeutics compare to Eliem Therapeutics?

Summary

How does Silverback Therapeutics compare to Neoleukin Therapeutics?

Summary

How does Silverback Therapeutics compare to Whitehawk Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBTX vs. The Competition

Silverback Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silverback Therapeutics (SBTX) Competitors

SBTX vs. AVTE, LWAC, ELYM, NLTX, and WHWK

How does Silverback Therapeutics compare to Aerovate Therapeutics?

Summary

How does Silverback Therapeutics compare to LightWave Acquisition?

Summary

How does Silverback Therapeutics compare to Eliem Therapeutics?

Summary

How does Silverback Therapeutics compare to Neoleukin Therapeutics?

Summary

How does Silverback Therapeutics compare to Whitehawk Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBTX vs. The Competition

Silverback Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools